Results 181 to 190 of about 3,049 (238)
Some of the next articles are maybe not open access.
Ldl-Apheresis on Affine Haemosorbents
Biomaterials, Artificial Cells and Artificial Organs, 1990There were synthesized new hemosorbents for selective removal of LDL, based on macroporous silica, immobilised by heparine (sorbent 1) and chytozane-sulphate (sorbent 2). Experimental data showed satisfactory hemo- and biocompatibility of the new sorbents. No significant alterations in biochemical parameters were observed.
Yu. M. Lopukhin +4 more
openaire +3 more sources
Atherosclerosis, 2003
Low density lipoprotein (LDL) apheresis provides a safe and effective means of treating patients with homozygous familial hypercholesterolaemia (FH). It also has a role in preventing the progression of coronary artery disease in heterozygotes and others with severe dyslipidaemia who are refractory to or intolerant of high doses of lipid-lowering drugs.
openaire +2 more sources
Low density lipoprotein (LDL) apheresis provides a safe and effective means of treating patients with homozygous familial hypercholesterolaemia (FH). It also has a role in preventing the progression of coronary artery disease in heterozygotes and others with severe dyslipidaemia who are refractory to or intolerant of high doses of lipid-lowering drugs.
openaire +2 more sources
Release of microparticles in LDL apheresis
Transfusion and Apheresis Science, 2001Particle contamination of blood always takes place in extracorporeal systems and few studies have been conducted to evaluate potential risks. Particle concentration was measured in the efferent blood line on original equipment for two established LDL elimination procedures (DALI) (Fresenius) and Liposorber (Kaneka).
Roland E. Winkler +5 more
openaire +3 more sources
What’s going on in LDL apheresis
Transfusion and Apheresis Science, 2007(1) immunoadsorption (IMA), which consists of selective removal of LDL from plasma using polyclonal sheep anti-LDL antibodies; (2) direct adsorption of lipoprotein from whole blood, hemoperfusion using non-hemolytic polyacrylate-coated polyacrilamide gel (DALI), with the advantage of a shorter procedure time; (3) presently available, a new system of ...
Patrizia Accorsi, Daniela Onofrillo
openaire +3 more sources
Transfusion and Apheresis Science, 2007
LDL apheresis is a technology used worldwide for the treatment of refractory familial hypercholesterolemia [1]. In Italy, this extracorporeal treatment has been applied for the last 20 years, firstly by using plasma exchange and cascade filtration and by the end of the 1980’s introducing the first selective systems for LDL apheresis on a routine basis.
openaire +3 more sources
LDL apheresis is a technology used worldwide for the treatment of refractory familial hypercholesterolemia [1]. In Italy, this extracorporeal treatment has been applied for the last 20 years, firstly by using plasma exchange and cascade filtration and by the end of the 1980’s introducing the first selective systems for LDL apheresis on a routine basis.
openaire +3 more sources
Current Treatment Options in Cardiovascular Medicine, 2006
Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy.
openaire +3 more sources
Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy.
openaire +3 more sources
Treatment of Severe Hypercolesterolaemia by LDL-Apheresis
Biomaterials, Artificial Cells and Immobilization Biotechnology, 1991The most severe forms of hypercholesterolaemia scarcely respond to diet and conventional drugs administration and need, therefore, alternative treatments. Terapeutic Plasma Exchange demonstrated an improved survival of subjects with Familial Hypercholesterolaemia (FH) in spite of its limitations.
SCARPATO, NICOLA +6 more
openaire +4 more sources
The Dresden Apheresis Center – experience with LDL apheresis and immunoadsorption
Atherosclerosis Supplements, 2009The first apheresis center in former German Democratic Republic was established in Dresden November 1990 following the reunification of Germany. We here summarize the activities of this center to date. From the center's establishment until the end of July 2009 13,291 sessions of therapeutic apheresis have been performed.
Ulrich Julius +4 more
openaire +3 more sources
Comparison of different LDL apheresis methods
Expert Review of Cardiovascular Therapy, 2008This article presents the generally accepted indications for LDL apheresis treatment. The available LDL apheresis methods differ with respect to acute relative reductions of LDL cholesterol; mean values after the LDL apheresis treatments are not different. Serum triglycerides, HDL-cholesterol, and lipoprotein(a) are also acutely reduced.
Ulrich Julius +5 more
openaire +3 more sources
Applications of LDL-apheresis in nephrology
Clinical and Experimental Nephrology, 2008LDL-apheresis (LA) was originally used for familial hyperlipidemia, and then in Japan extended to use for the treatment of patients with peripheral arterial disease (PAD) and nephrotic syndrome due to steroid-resistant focal glomerular sclerosis (FGS). The reason why this treatment is applicable for these disorders is due to the fact that LA exerts its
openaire +3 more sources